SERVICIOS
Evaluación económica
Análisis de Coste-Efectividad / Coste-Utilidad, Minimización de Costes, MDCA, eventos discretos,. Tanto adaptación como desarrollo de modelos ‘de novo’.
Precio y reembolso
Acompañamiento y asesoría durante el proceso de negociación, elaboración de dossiers y materiales de apoyo, elaboración de análisis de impacto presupuestario, metaplan y mock negociation
Acceso al mercado (Market Access)
Análisis del entorno, historia de valor, planes de acceso al mercado, herramientas interactivas, modelos de compra innovadores (pago por resultados, riesgo compartido), advisory boards
Outcomes research & medical writing
Estudios RWE (retrospectivos, obsevacionales), estudios de calidad de vida, análisis estadístico, medical writing
Formación
En evaluación económica, técnicas de modelización, sistema sanitario, acceso al mercado, etc
- Comparison of the efficiency of digital pathology with the conventional methodology for the diagnosis of biopsies in an anatomical pathology laboratory in Spain
- Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain
- Cost-effectiveness of a machine learning risk prediction model (LungFlag) in the selection of high-risk individuals for non-small cell lung cancer screening in Spain
- Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis
- Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain
- Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
- Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain
- Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
- Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
- Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers
- Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective
- Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain
- Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario
- Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019
- Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)
- Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)
- Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain
- Papel protector de las actuales vacunas para las variantes del virus SARS-CoV-2 y la COVID persistente
- Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
- Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD
- Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
- Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
- Cost-effectiveness analysis of febuxostat in patients with gout in Spain
Hygeia Consulting S.L.
Paseo de la Castellana 18, 7-floor 28046, Madrid (España)
(+34) 91 794 28 18